← Back to patent-cliff list
Cyproheptadine Hydrochloride/Prazosin Hydrochloride
Tier C — Watch / tradeCyproheptadine Hydrochloride/Prazosin Hydrochloride
Kinnov Therapeutics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Histamine receptor, Adrenoceptors, 5-HT2, ADRA1A, ADRA1, Bradykinin receptors, HRH1
Indications (approved)：Alcohol abuse
Regional status
US
-
EU
Phase II
2023-11-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cyproheptadine Hydrochloride/Prazosin Hydrochloride?
Approved indications include: Alcohol abuse.
When does the Cyproheptadine Hydrochloride/Prazosin Hydrochloride patent expire?
No public expiry year is available for Cyproheptadine Hydrochloride/Prazosin Hydrochloride yet; this page updates once verified.
How do I get a quote for Cyproheptadine Hydrochloride/Prazosin Hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-02